KROS - Keros Therapeutics Inc Company Long-Term Liabilities

Graphic logo of Keros Therapeutics Inc (KROS)

Keros Therapeutics (KROS) is developing advanced therapies through partnerships with scientific centers, creating synergy to combat bone pathologies and anemia. Innovative protein modulation and a patent shield ensure high margins. This price chart demonstrates a long-term debt structure, which stands at 0.01. The company's growth relies on the study of tissue regeneration and elatercept test results for pulmonary hypertension.

Company Long-Term Debts: Keros Therapeutics (KROS) for 07/04/2022 - 11/01/2026

Keros Pharma (KROS) - metric breakdowns and financial figures

- market value and analyst target forecast:
Market Price kerostx.com|KROS - Analyst Consensus Forecast
- market capitalization statistics:
Market Valuation Keros Therapeutics|KROS - Enterprise Value
- shareholders' equity book value data:
Net Assets per Share Keros Therapeutics|KROS - Book Capitalization|Market Capitalization to Book Value Ratio kerostx.com|KROS - Aggregate Company Assets
- business debt structure and liquidity details:
Debt to Equity Keros Therapeutics|KROS - Long-Term Debt to Capital|Short-Term Debt to Capital Coefficient Keros Corp|KROS - Company Total Debt|Debts to Book Capitalization Ratio Keros Therapeutics|KROS - Company Long-Term Debts|Short-Term Debt Keros Therapeutics|Immediate Liquidity Ratio kerostx.com
- company profitability and valuation multiples indicators:
KROS - Net Income
Fundamental company valuation:kerostx.com, KROS
Manufactured products of Keros Therapeutics

When selecting an issuer, fundamental multiples must be compared with the debt load to assess the stability of the capital structure. By analyzing the issuer's long-term liabilities, an investor can determine the volume of core borrowings required by Keros Therapeutics (KROS) to finance its TGF-beta platform and diversified pipeline, where the dynamics of debt repayment or accumulation reflect the balance between investment growth and the binary risks of clinical trials.

Who Keros Therapeutics competes with

vrtx.com (VRTX) - Long-Term Debt|Alnylam - Company Long-Term Debts|Insmed Inc. (INSM) - Company Long-Term Liabilities|UTHR: Company Long-Term Debts|BMRN - Long-Term Debt Volume|BBIO (BridgeBio Pharma, Inc.) - Company Long-Term Debts|Company Long-Term Debts BGM Group Corp|Company Long-Term Debt Cogent Biosciences, Inc. (COGT)|Company Long-Term Debt XERS (Xeris Biopharma Holdings, Inc.)|Company Long-Term Debts ARCT (Arcturus Pharma)|Long-Term Debt Volume Eton Corp (ETON)|KMDA: Company Long-Term Liabilities|Long-Term Liabilities FULC|ABEO: Company Long-Term Debts|Long-Term Debt Mereo BioPharma Group plc (MREO)|PLX (Protalix) - Company Long-Term Debts|Company Long-Term Indebtedness PLRX (Pliant Rx)|Company Long-Term Liabilities APLT (Applied Therapeutics, Inc.)|RNTX (aileronrx.com) - Company Long-Term Loans and Borrowings|Company Long-Term Debt Gelteq GELS|AYTU (Aytu BioPharma Inc) - Long-Term Liabilities|Chemomab - Company Long-Term Debts|Company Long-Term Loans and Borrowings SRXH (SRx Health Solutions Inc.)|PLRZ: Company Long-Term Debts|Aeterna Zentaris Inc. (AEZS) - Company Long-Term Debts|Company Long-Term Debt Cyclo Therapeutics, Inc.|INZY: Company Long-Term Loans and Borrowings|Company Long-Term Debt Reneo Pharma (RPHM)|Company Long-Term Liabilities COSCIENS Bio CSCI